Highest-materiality recent filing
Bowhead Q1 GWP +24% to $216.7M, net income $16.0M; amends quota share with AFMIC
GWP increased 24% to $216.7M; net income $16.0M ($0.48 diluted EPS), adjusted EPS also $0.48.
Bowhead Q4 gross written premiums up 21.3% to $224.1M; FY adjusted EPS $1.65
Q4 net income $14.8M ($0.44 diluted EPS); adjusted net income $15.5M ($0.47 diluted).
Bowhead Specialty secures $35M revolving credit facility with PNC Bank, maturing Nov 2027
Facility is a $35M senior secured revolving credit agreement; no borrowings made at closing (Nov 26, 2025).
Bowhead closes $150M of 7.750% Senior Notes due 2030, repays credit facility
Issued $150M aggregate principal of 7.750% Senior Notes due December 1, 2030.
Bowhead Q3 GWP +17.5% to $231.5M; adj. EPS $0.47
Gross written premiums $231.5M (+17.5% YoY); casualty division led with +20.4%.
Bowhead Specialty elects Price Lowenstein to Board, expanding to 11 members
Price Lowenstein elected to Board, effective Oct 2, 2025; Board expands from 10 to 11 members.
Selling stockholder GPC Partners sold 2,000,000 common shares in public secondary offering.
Bowhead Specialty Q2 2025: GWP up 32.4% to $232.4M; net income soars 123% to $12.3M
Gross written premiums $232.4M (+32.4% YoY); net income $12.3M ($0.36 diluted EPS).
Bowhead files $300M universal shelf S-3; says no imminent capital raise
Filed two Form S-3 registration statements on June 6, 2025: a $300M universal shelf and a registration rights shelf.
Bowhead Q1 gross premiums up 26% to $174.8M; net income $11.4M up 60%
Gross written premiums $174.8M (+26.3% YoY); net income $11.4M ($0.34 diluted EPS), up 60%.
Bowhead Specialty furnishes Q4 2024 investor presentation without specific financial data
Investor presentation for period ended Dec 31, 2024 made available on Feb 28, 2025.
Bowhead Specialty Q4 net income $13.6M; gross premiums +26% to $184.8M, FY +37% to $695.7M
Q4 gross written premiums $184.8M (+26.3% YoY); FY $695.7M (+37%).
Bowhead Specialty sets 2025 annual meeting for May 1; proposal deadline Feb 7
2025 annual meeting scheduled for Thursday, May 1, 2025.
Bowhead Specialty Q3 gross written premiums up 32.3% to $197M; net income $12.1M
Gross written premiums $197.0M, up 32.3% year over year.
Bowhead Specialty: Director Stein resigns after secondary offering; Schnidman appointed
Jack Stein resigned effective Oct 25, 2024 as GPC Fund's nominee due to reduced board nomination rights after underwritten secondary offering. No disagreement.
Bowhead Specialty reports preliminary Q3 2024: GWP up 27-34% YoY, net income $11.5-12.5M
Gross written premiums expected $193M-$200M, up 27%-34% YoY.
Bowhead Specialty Q2 2024 supplemental report available; no specific results in filing text
Supplemental report covering Q2 2024 (June 30, 2024) furnished as Exhibit 99.1.
Bowhead Specialty Q2 gross written premiums up 50.4% to $175.5M, net income $5.5M
Gross written premiums grew 50.4% YoY to $175.5 million in Q2 2024.
Effective October 25, 2024, Jack Stein, who was one of GPC Partners Investments (SPV III) LP’s (“GPC Fund”) nominees to the board of directors (the “Board”) of Bowhead Specialty Holdings Inc. (the “Company”) pursuant to GPC Fund’s rights under the Board Nominee Agreement, dated as of May 23, 2024, between the Company and GPC Fund, resigned from the Board.
On October 30, 2024, the Board elected Dr. Ava Schnidman to the Board, effective October 30, 2024.
Max materiality 0.85 · Median 0.60 · Most common event earnings